- Home
- TEVA
as 10-07-2025 3:28pm EST
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
| Founded: | 1901 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 21.2B | IPO Year: | N/A |
| Target Price: | $25.57 | AVG Volume (30 days): | 10.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.46 - $22.80 | Next Earning Date: | 11-05-2025 |
| Revenue: | $16,628,000,000 | Revenue Growth: | 2.08% |
| Revenue Growth (this year): | 4.07% | Revenue Growth (next year): | 0.81% |
Latest Teva Pharmaceutical Industries Limited News
TEVA Breaking Stock News: Dive into TEVA Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Teva (TEVA) Is Up 9.2% After New Schizophrenia Drug Data and Innovation Shift - What’s Changed
Zacks
6 days ago
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
Insider Monkey
6 days ago
UBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00
Insider Monkey
6 days ago
Truist Securities Reaffirms Its Buy Rating for Teva Pharmaceutical Industries Limited (TEVA)
Zacks
14 days ago
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
Business Wire
14 days ago
Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
Morningstar Research
15 days ago
Analyst Report: Teva Pharmaceutical Industries Limited
Zacks
16 days ago
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
Compare TEVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TEVA Teva Pharmaceutical Industries Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.